Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2004

01-06-2004 | Original Article

Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer

Authors: Satoko Matsueda, Kazuhiko Kobayashi, Yoichi Nonaka, Masanori Noguchi, Kyogo Itoh, Mamoru Harada

Published in: Cancer Immunology, Immunotherapy | Issue 6/2004

Login to get access

Abstract

Purpose

Prostate cancer refractory to hormonal manipulation requires new treatment modalities. In the present study we attempted to identify prostate stem cell antigen (PSCA)-derived peptides immunogenic in HLA-A2+ prostate cancer patients in order to develop peptide-based immunotherapy against hormone-refractory prostate cancer (HRPC).

Methods

Eleven different PSCA-derived peptides, which were prepared based on the HLA-A2 binding motif, were examined to determine whether they would be recognized by cellular and humoral immune responses in 12 HLA-A2+ patients (11 with HRPC and 1 with non-HRPC).

Results

Among the PSCA-derived peptides, PSCA 7–15 and PSCA 21–30 peptides effectively induced HLA-A2-restricted peptide-specific and tumor-reactive cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear cells (PBMCs) of HLA-A2+ patients. The PSCA 21–30 peptide was capable of inducing peptide-specific CTLs in both cancer patients and healthy donors, whereas the PSCA 7–15 peptide was immunogenic in only cancer patients. Immunoglobulin G (IgG) reactive to the PSCA 21–30 peptide was detected in plasma of most patients and healthy donors, whereas IgG reactive to PSCA 7–15 was undetectable in all cases. These results indicate that the former peptide elicits both cellular and humoral immune responses in both patients and healthy donors, whereas the latter elicits only cellular responses in patients.

Conclusion

These two PSCA peptides should be considered for use in clinical trials of immunotherapy for HLA-A2+ HRPC patients.
Literature
1.
Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 81:267CrossRef
2.
Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89:293PubMed
3.
Correale P, Walmsley K, Zaremba S, Zhu MZ, Schlom J, Tsang KY (1998) Generation of human cytotoxic T lymphocyte lines directed against prostate-specific (PSA) employing a PSA oligoepitope peptide. J Immunol 161:3186PubMed
4.
Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M (2001) Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 60:5522
5.
Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics. CA Cancer J Clin 50:7PubMed
6.
Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE (2000) Postate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastases in prostate cancer. Oncogene 19:1288CrossRefPubMed
7.
Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K (2003) Prostate-specific antigen-derived epitopes capable of indcing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 57:152
8.
Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164:5508PubMed
9.
Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51:219CrossRefPubMed
10.
Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M (2002) Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 8:3885PubMed
11.
Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A, Itoh K (2001) Identification of lck-derived peptides capable of inducing HLA-A2-restricted tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 94:237CrossRefPubMed
12.
Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakazugi H (2001) Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 166:1508PubMed
13.
Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88:633PubMed
14.
Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth MP, Rieber EP (2002) Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 102:390CrossRefPubMed
15.
Kittlesen D, Thompson LW, Gulden PH, Skiller JCA, Colella TA, Shabanowitz JA, Hunt DR, Engelhard VH, Slingluff JC (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 160:2099PubMed
16.
Kobayashi K, Noguchi M, Itoh K, Harada M (2003) Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 94:622PubMed
17.
Lalaniel N, Laniado ME, Abel PD (1997) Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16:29CrossRefPubMed
18.
Meadows L, Wang W, den Haan JMM, Drijfhout JW, Shabanowitz J, Pierce R, Agulnik AI, Bishop CE, Hunt DF, Goulmy E, Engelhard VH (1997) The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6:273PubMed
19.
Murphy G.P, Tjoa BA, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371PubMed
20.
Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73CrossRefPubMed
21.
Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39:54CrossRefPubMed
22.
Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K (2002) Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32:826CrossRefPubMed
23.
Ohkouchi S, Yamada A, Imai N, Mine T, Harada K, Shichijo S, Maeda Y, Saijo Y, Nukiwa T, Itoh K (2002) Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 59:259CrossRefPubMed
24.
Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163PubMed
25.
Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC (1998) Induction of prostate tumor-specific CT8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36:129CrossRefPubMed
26.
Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P (1999) High frequencies of naïve Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705CrossRefPubMed
27.
Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735CrossRefPubMed
28.
Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281PubMed
29.
Tamura M, Nishizaka S, Maeda Y, Ito M, Harashima N, Harada M, Shichijo S, Itoh K (2001) Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 92:762PubMed
30.
Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G (1996) Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65CrossRefPubMed
31.
Xue BH, Zhang Y, Sosman J, Peace DJ (1997) Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30:73PubMed
Metadata
Title
Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer
Authors
Satoko Matsueda
Kazuhiko Kobayashi
Yoichi Nonaka
Masanori Noguchi
Kyogo Itoh
Mamoru Harada
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0464-x

Other articles of this Issue 6/2004

Cancer Immunology, Immunotherapy 6/2004 Go to the issue

Original Article

Dendritic cells are dysfunctional in patients with operable breast cancer

Original Article

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells

Original Article

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

Original Article

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines

Original Article

Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody

Opinion Paper

The effect of aging on cellular immunity against cancer in SR/CR mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits